Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-26

Study Completion Date

2027-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present research project aims to study the effects of bariatric surgery and liraglutide administration (in patients already selected for one of these procedures) on two cognitive-behavioral processes partially supported by distinct brain networks: automatic approach tendencies (underpinned by the cue-reactivity network) and behavioral inhibition (underpinned by the cue-regulation network). Additionally, the investigators aim to study how these processes may be modulated by satiety. The secondary objective of the project includes identifying cognitive-behavioral markers that can predict the response to these treatments.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Experimental and meta-analytic neuroimaging studies have highlighted two primary brain networks whose functioning or structure is altered in patients with obesity: (i) the "cue-reactivity network," involved in sensory, hedonic, and motivational responses to food, and (ii) the "cue-regulation network," more prominently involved in attentional, decision-making, and inhibitory processes. In line with this theoretical framework, weight loss induced by pharmacological treatments or bariatric surgery is associated with a partial recovery of the functioning and structure of these brain networks.

Following a sleeve gastrectomy, obese patients exhibit reduced activity in the reward circuit and increased activity in the inhibitory control circuit in response to high-calorie food images, suggesting a normalization of brain responses to food after bariatric surgery. Moreover, these changes in brain functionality may be accompanied by increased gray matter density in the prefrontal cortex, which persists for up to 12 months following sleeve gastrectomy or Roux-en-Y gastric bypass.

Pharmacologically, the administration of glucagon-like peptide-1 receptor (GLP-1) agonists-such as liraglutide, semaglutide, and exenatide-has proven effective in treating diabetes and promoting weight loss. fMRI studies have shown that intravenous administration of exenatide (vs. placebo) in patients with obesity and type 2 diabetes reduces neurofunctional activity in key nodes of the cue-reactivity network (e.g., amygdala, putamen, insula) in response to high-calorie food images. Furthermore, this effect is nullified if exenatide administration is preceded by GLP-1 receptor blockade.

However, it remains unclear whether such surgical or pharmacological treatments are accompanied by changes in cognitive processes associated with reactivity to edible stimuli or behavioral inhibition, and whether these contribute to an improved post-operative response to satiety.

This research project thus aims to study the effects of bariatric surgery and liraglutide administration (in patients already selected for one of these procedures) on two cognitive-behavioral processes partially supported by distinct brain networks: automatic approach tendencies (underpinned by the cue-reactivity network) and behavioral inhibition (underpinned by the cue-regulation network). Additionally, the investigators aim to study how these processes may be modulated by satiety. The secondary objective of the project involves identifying cognitive-behavioral markers that could predict responses to these treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity and Overweight

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Obesity Bariatric surgery food cognition liraglutide

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bariatric Surgery

Patients submitted to bariatric surgery

No interventions assigned to this group

Liraglutide

Patients submitted to liraglutide treatment

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects of any ethnicity, aged between 20 and 60 years.
* BMI equal to or greater than 30 kg/m².
* No history of neurological or psychiatric disorders, as confirmed through medical history and neuropsychological screening.
* Signed informed consent and willingness to comply with all study procedures.
* Patients scheduled for surgery, treatment with liraglutide, or a dietary regimen.

Exclusion Criteria

* Previous diagnosis of significant neurological conditions (e.g., brain injury or dementia) or major psychiatric disorders.
* Current or past psychopharmacological therapy, if prolonged.
* BMI lower than 30 kg/m².
* Lack of signed informed consent.
* Severe medical conditions, including but not limited to: hypertension, significant cardiac disease, or other disorders that may compromise patient safety.
* Confirmed pregnancy through self-report and/or breastfeeding.

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS Ospedale Galeazzi-Sant'Ambrogio

Milan, Milan, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Eraldo Paulesu, MD

Role: CONTACT

Phone: +390264483748

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC2024

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

BALANCE

Identifier Type: -

Identifier Source: org_study_id